The anti-inflammatory action of Ketanserin was evident also when considering the levels of bowel and plasmatic cytokines: indeed, the 5-HT2A blocker was able to globally revert the increase in inflammatory cytokines evoked in TNBS colitis both in colon and in plasma (Figure 4), where TNFα and IL-1β concentrations were reduced, respectively, up to 5 (P < 0.05) and 2.5 times compared to C animals. This evidence concerns the gene HTR2A and colitis.